By Daniella Parra
Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies.
The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab, it said.
“This study is an important validation of caffeine’s potential to address critical viscosity challenges in developing subcutaneous biologics,” said Robert Mahoney, Ph.D., Chief Scientific Officer of Comera. “The results further support the rapid dissociation of caffeine upon subcutaneous injection and that caffeine does not affect pharmacokinetic profiles of the model monoclonal antibody, both of which are critical features of a successful subcutaneous formulation.”